Koizumi Hideki

写真a

Researcher Number(JSPS Kakenhi)

20551500

Current Affiliation Organization 【 display / non-display

  • Duty   University of the Ryukyus   Graduate School of Medicine  

External Career 【 display / non-display

  • 2012.06
     
     

     

  • 2012.07
    -
    2016.09

    Tokyo Women's Medical University  

  • 2016.10
    -
    2017.09

    Tokyo Women's Medical University  

  • 2017.10
     
     

     

Research Interests 【 display / non-display

  • 画像診断

  • 眼循環

  • 眼科学

  • 網膜硝子体

  • 黄斑

Research Areas 【 display / non-display

  • Life Science / Ophthalmology

Published Papers 【 display / non-display

  • Retrospective exploratory analyses on gender differences in determinants for incidence and progression of diabetic retinopathy in Japanese patients with type 2 diabetes mellitus.

    Nakayama Y, Yamaguchi S, Shinzato Y, Okamoto S, Millman JF, Yamashiro K, Takemoto N, Uema T, Arakaki K, Higa M, Koizumi H, Shimabukuro M, Masuzaki H

    Endocrine journal ( 一般社団法人 日本内分泌学会 )  68 ( 6 ) 655 - 669   2021.06

    Type of publication: Research paper (scientific journal)

     View Summary

    <p>Gender differences in risks for macrovascular complications in type 2 diabetes mellitus (T2DM) have been well established. However, the impact of gender differences on diabetic retinopathy (DR) has not been fully elucidated. We therefore retrospectively explored gender-specific determinants for DR in patients with T2DM in a small sized Japanese cohort in Okinawa. There were 214 patients who were diagnosed as no DR (<i>n</i> = 142) and non-proliferative DR (<i>n</i> = 72) in 2009. During the follow-up of median 7 years, 41/142 of incidence, 26/72 of progression, and 67/214 of incidence and progression were observed, respectively. DR was assessed using the modified international clinical DR severity scales. The risks for incidence, progression as well as incidence and progression of DR were comparable between men and women, respectively. Cox proportional hazard models in multivariate analyses demonstrated that the only common determinant in both men and women for DR was the duration of T2DM. Regarding gender-specific determinants, lower level of serum albumin in men as well as higher HbA1c, lower level of estimated glomerular filtration rate, and lower level of serum uric acid in women were extracted, respectively. Although precise mechanisms for such gender-specific determinants of DR still remain unsolved, the present study would highlight a couple of factors associated with gender-specific determinants for DR in a limited numbers of Japanese cohort. Prospective observational studies on gender-specific determinants of DR in a large scale cohort are warranted to further clarify underlying mechanisms.</p>

  • Short axial length and hyperopic refractive error are risk factors of central serous chorioretinopathy.

    Terao N, Koizumi H, Kojima K, Kusada N, Nagata K, Yamagishi T, Yoneda K, Yoshii K, Kinoshita S, Sotozono C

    The British journal of ophthalmology ( British Journal of Ophthalmology )  104 ( 9 ) 1260 - 1265   2020.09 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    BACKGROUND/AIMS: To evaluate the axial length (AL) and refractive status in central serous chorioretinopathy (CSC). METHODS: This retrospective observational case series involved 140 patients with CSC (180 eyes) and 78 age-matched and gender-matched control subjects. A detailed ophthalmic examination was performed, including an interferometer measurement of AL. Multimodal imaging comprised colour fundus photography, fluorescein angiography, indocyanine green angiography, fundus autofluorescence photography and spectral domain optical coherence tomography. RESULTS: Eighty eyes of 40 patients were categorised into the bilateral-CSC (b-CSC) group and 100 eyes of 100 patients were categorised into the unilateral-CSC (u-CSC) group. AL of the b-CSC (23.19 mm) and u-CSC (23.75 mm) groups was significantly shorter than that of the control (24.85 mm) group (p<0.001 for both). Moreover, AL was significantly shorter in the b-CSC group than in the u-CSC group (p=0.020). Spherical equivalent (SE) in the b-CSC (0.25 D) group was significantly greater than in the u-CSC (-0.81 D) and control (-1.38 D) groups (p<0.001 for both). Gender (male; OR 4.55; 95% CI 1.13 to 18.40; p=0.033), AL (OR 0.38; 95% CI 0.23 to 0.63; p<0.001), area of choroidal vascular hyperpermeability (OR 1.08; 95% CI 1.03 to 1.13; p=0.002) and presence of descending tract (OR 7.22; 95% CI 1.86 to 28.00; p=0.004) were the variables found to be significantly associated with b-CSC via multiple regression analyses. CONCLUSION: Anatomical features, such as shorter AL and greater SE, may be associated with the pathogenesis of CSC.

  • Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.

    Maruko I, Ogasawara M, Yamamoto A, Itagaki K, Hasegawa T, Arakawa H, Nakayama M, Koizumi H, Okada AA, Sekiryu T, Iida T

    Ophthalmology. Retina ( Ophthalmology Retina )  4 ( 8 ) 767 - 776   2020.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    PURPOSE: To report the 2-year outcomes of intravitreal aflibercept injections (IAIs) in Japanese patients with neovascular age-related macular degeneration (AMD) using a 1-month adjusted treat-and-extend (TAE) regimen. DESIGN: Multicenter, prospective, nonrandomized, interventional study. PARTICIPANTS: Ninety-seven eyes of 97 patients with treatment-naive AMD were studied at 3 tertiary ophthalmological institutions. METHODS: The patients were treated with 3 consecutive monthly IAIs followed by the TAE regimen with a 1-month adjustment for a maximum of 3 months. Our TAE regimen allowed us to shorten and extend the treatment intervals even after a 3-month or 1-month treatment interval, or both, were reached. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), and subfoveal choroidal thickness (SCT) were analyzed. MAIN OUTCOME MEASURES: The mean changes in the BCVA, CRT, and SCT from the baseline to 2 years after initiating the treatment were determined. In addition, the number of injections also was determined. RESULTS: The mean BCVA significantly improved from 0.27 logarithm of the minimum angle of resolution (logMAR) units to 0.14 logMAR at 2 years (P < 0.01). The mean CRT decreased significantly from 307±132 μm to 202±76 μm at 2 years (P < 0.01). The mean SCT decreased significantly from 247±106 μm to 203±96 μm at 2 years (P < 0.01). Seventy eyes (72.2%) showed a dry macula at 2 years. The treatment interval at 2 years was 1 month in 20 eyes (20.6%), 2 months in 18 eyes (18.6%), and 3 months in 59 eyes (60.8%). In 49 (50.5%) eyes with a 3-month treatment interval immediately after the loading phase, no fluid was seen in 25 eyes (51.0%) for the duration of this study. The rest had switched to a more frequent scheme. The mean number of injections during the 2-year period was 13.0±3.9. CONCLUSIONS: Intravitreal aflibercept injections with a 1-month adjusted TAE regimen significantly improved the BCVA and CRT with a reduced number of injections at 2 years. The treatment interval was adjusted to extend to 3 months in 60% and to shorten to 1 month in 20% of the eyes at 2 years.

  • Scleral Thickness in Central Serous Chorioretinopathy.

    Imanaga N, Terao N, Nakamine S, Tamashiro T, Wakugawa S, Sawaguchi K, Koizumi H

    Ophthalmology. Retina ( Ophthalmology Retina )  5 ( 3 ) 285 - 291   2020.07 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    PURPOSE: To evaluate scleral thickness in central serous chorioretinopathy (CSC) using anterior segment (AS) OCT. DESIGN: Retrospective, comparative study. PARTICIPANTS: Forty-seven eyes of 40 patients with CSC and 53 eyes of 47 age- and gender-matched normal control participants. METHODS: Spherical equivalent, axial length, subfoveal choroidal thickness, and scleral thickness were compared between the CSC and control groups. Scleral thickness was measured by AS OCT 6 mm posterior to the scleral spur in 4 directions. MAIN OUTCOME MEASURE: Scleral thickness in CSC eyes. RESULTS: No differences were found between the 2 groups in age, gender, spherical equivalent, or axial length. Subfoveal choroidal thickness was significantly greater in CSC eyes than in normal control eyes (424.0 ± 101.4 μm vs. 324.3 ± 91.8 μm; P < 0.001). Scleral thickness was significantly greater in CSC eyes than in normal control eyes at the superior (429.4 ± 50.3 μm vs. 395.2 ± 55.4 μm; P = 0.005), temporal (447.7 ± 45.7 μm vs. 396.5 ± 64.1 μm; P < 0.001), inferior (455.7 ± 81.2 μm vs. 437.8 ± 46.9 μm; P = 0.022), and nasal (454.9 ± 44.7 μm vs. 416.6 ± 51.2 μm; P = 0.001) points. CONCLUSIONS: Scleral thickness measured by AS OCT was significantly greater in CSC eyes than in normal control eyes, although no differences were found in spherical equivalent or axial length. Thick sclera may have a role in the pathogenesis of CSC.

  • Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study.

    Koizumi H, Yamamoto A, Ogasawara M, Maruko I, Hasegawa T, Itagaki K, Sekiryu T, Okada AA, Iida T

    Japanese journal of ophthalmology ( Japanese Journal of Ophthalmology )  64 ( 4 ) 338 - 345   2020.07 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    PURPOSE: To evaluate the development and rate of growth in macular atrophy after intravitreal injections of aflibercept (IVAs) for neovascular age-related macular degeneration (AMD) over a 2-year period. STUDY DESIGN: Retrospective, interventional, consecutive case series. METHODS: This study included 94 eyes of 92 patients with treatment-naïve AMD involving the foveal center treated with IVAs at 3 university hospitals in Japan. The patients underwent IVAs bimonthly after 3 initial monthly doses in the first year. The protocol was converted to a treat-and-extend regimen in the second year. The incidence and growth rate of macular atrophy were quantified based on hypoautofluorescence detected by fundus autofluorescence images. Additionally, possible background factors related to the development and rate of growth of macular atrophy were investigated. RESULTS: Of 94 eyes, 39 (41.5%) had typical AMD and 55 (58.5%) had polypoidal choroidal vasculopathy. Ten eyes (10.6%) had macular atrophy at the baseline. Of the remaining 84 eyes, 14 (16.7%) had developed new macular atrophy at 2 years, the square root of the growth rate of atrophy was 0.52 mm/year. In multivariate analyses, a poorer best-corrected visual acuity (P = 0.01) and the presence of intraretinal fluid (P = 0.04) at baseline were found to be the independent predictors for the development of macular atrophy. No factors were found that were significantly related to the growth rate of the macular atrophy. CONCLUSIONS: Our study determined the incidence and rate of growth of macular atrophy after IVAs for neovascular AMD in clinical settings. Eyes with vision reduction and intraretinal fluid at the baseline develop macular atrophy more frequently after IVAs for neovascular AMD.

display all >>

Books 【 display / non-display

  • Choroidal Disorders

    古泉 英貴 ( Part: Multiple Authorship ,  Imaging and diagnosis of polypoidal choroidal vasculopathy )

    Academic Press, London  2017

  • Fundus Autofluorescence, 2nd ed

    古泉 英貴 ( Part: Multiple Authorship ,  Polypoidal choroidal vasculopathy )

    Wolters Kluwer, Philadelphia  2016

Other Papers 【 display / non-display

  • 【自発蛍光で読み解く 眼底疾患】加齢黄斑変性と眼底自発蛍光

    今永 直也, 古泉 英貴

    眼科グラフィック ( (株)メディカ出版 )  8 ( 5 ) 547 - 559   2019.10

     

  • 【いちばんやさしいOCTの撮りセツ】疾患別OCT画像の撮り方,見方 まずはこれだけ3疾患 加齢黄斑変性

    冨山 亜季子, 古泉 英貴

    眼科ケア ( (株)メディカ出版 )  21 ( 10 ) 1016 - 1025   2019.10

     

  • 高齢者糖尿病における糖尿病性網膜症の発症及び悪化要因に関する臨床疫学的後方視解析

    新里 幸子, 中山 良朗, 比嘉 盛丈, 新垣 孝一郎, 島袋 充生, 古泉 英貴, 益崎 裕章

    糖尿病 ( (一社)日本糖尿病学会 )  62 ( 9 ) 611 - 611   2019.09

     

  • 線維柱帯切開術(眼内法)の予後因子の検討

    新垣 淑邦, 酒井 寛, 力石 洋平, 與那原 理子, 上原 千晶, 古泉 英貴

    日本緑内障学会抄録集 ( 日本緑内障学会 )  30回   138 - 138   2019.09

     

  • 急性原発閉塞隅角症の網膜血管密度および神経節細胞複合体

    力石 洋平, 酒井 寛, 新垣 淑邦, 與那原 理子, 古泉 英貴

    日本緑内障学会抄録集 ( 日本緑内障学会 )  30回   142 - 142   2019.09

     

display all >>

Academic Awards 【 display / non-display

  • Achievement Award

    2019.10   American Academy of Ophthalmology  

Grant-in-Aid for Scientific Research 【 display / non-display

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2021.04  -  2024.03 

    Direct: 2,800,000 (YEN)  Overheads: 3,640,000 (YEN)  Total: 840,000 (YEN)

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2021.04  -  2024.03 

    Direct: 2,800,000 (YEN)  Overheads: 3,640,000 (YEN)  Total: 840,000 (YEN)

  • choroidal blood flow mechanism using OCT angiography and laser speckle flowgraphy

    Grant-in-Aid for Scientific Research(C)

    Project Year: 2016.04  -  2019.03 

    Investigator(s): Maruko Ichiro, Maruko Ruka, Kawai Moeko, Okawa Yuka, Ishimaru Yuriko, Yokoyama Tatsuro, Kakehashi Mizuha, Hashimoto Eriko 

    Direct: 2,200,000 (YEN)  Overheads: 2,860,000 (YEN)  Total: 660,000 (YEN)

     View Summary

    Usually, choroidal blood flow cannot be visualized by optical coherence tomography angiography (OCTA), but we reported it was possible in cases of retinal pigment epithelial atrophy, some cases of pathologic myopia, choroideremia and unilateral acute idiopathic maculopathy (UAIM), etc. These studies suggest that the inability to visualize choroidal blood flow is due to the light shielding effect of retinal pigment epithelium and choriocapillaris. Therefore, we have devised a method that enables to visualize to some extent even normal eyes and cases of choroidal thickening by subtracting the artifacts due to these light shielding effects.

  • choroidal blood flow mechanism using OCT angiography and laser speckle flowgraphy

    Grant-in-Aid for Scientific Research(C)

    Project Year: 2016.04  -  2019.03 

    Investigator(s): Maruko Ichiro, Maruko Ruka, Kawai Moeko, Okawa Yuka, Ishimaru Yuriko, Yokoyama Tatsuro, Kakehashi Mizuha, Hashimoto Eriko 

    Direct: 2,200,000 (YEN)  Overheads: 2,860,000 (YEN)  Total: 660,000 (YEN)

     View Summary

    Usually, choroidal blood flow cannot be visualized by optical coherence tomography angiography (OCTA), but we reported it was possible in cases of retinal pigment epithelial atrophy, some cases of pathologic myopia, choroideremia and unilateral acute idiopathic maculopathy (UAIM), etc. These studies suggest that the inability to visualize choroidal blood flow is due to the light shielding effect of retinal pigment epithelium and choriocapillaris. Therefore, we have devised a method that enables to visualize to some extent even normal eyes and cases of choroidal thickening by subtracting the artifacts due to these light shielding effects.

  • Tailor-made medicine of age-related macular degeneration using fluorescence of verteporfin

    Grant-in-Aid for Scientific Research(C)

    Project Year: 2015.04  -  2018.03 

    Investigator(s): Iida Tomohiro 

    Direct: 3,600,000 (YEN)  Overheads: 4,680,000 (YEN)  Total: 1,080,000 (YEN)

     View Summary

    Photodynamic therapy using verteporfin is an effective treatment for eyes with exudative age-related macular degeneration. To constract the tailor-made medicine of age-related macular degeneration, we examined fluorescence of verteporfin in vivo. Using fundus camera, we found fluorescence of verteporfin in retinal vessels and experimental choroidal neovascularization in rat eyes. However, we did not find fluorescence of verteporfin using fundus camera in eye with exudative age-related macular degeneration.

display all >>